- Home
- RQI vs ANIP Comparison
RQI vs ANIP Comparison
Compare RQI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- ANIP
- Stock Information
- Founded
- RQI 2002
- ANIP 2001
- Country
- RQI United States
- ANIP United States
- Employees
- RQI N/A
- ANIP N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- RQI Finance
- ANIP Health Care
- Exchange
- RQI Nasdaq
- ANIP Nasdaq
- Market Cap
- RQI 1.7B
- ANIP 2.0B
- IPO Year
- RQI N/A
- ANIP N/A
- Fundamental
- Price
- RQI $12.49
- ANIP $97.48
- Analyst Decision
- RQI
- ANIP Strong Buy
- Analyst Count
- RQI 0
- ANIP 9
- Target Price
- RQI N/A
- ANIP $89.11
- AVG Volume (30 Days)
- RQI 432.6K
- ANIP 400.8K
- Earning Date
- RQI 01-01-0001
- ANIP 11-07-2025
- Dividend Yield
- RQI 8.20%
- ANIP N/A
- EPS Growth
- RQI N/A
- ANIP N/A
- EPS
- RQI N/A
- ANIP N/A
- Revenue
- RQI N/A
- ANIP $747,399,000.00
- Revenue This Year
- RQI N/A
- ANIP $39.36
- Revenue Next Year
- RQI N/A
- ANIP $9.45
- P/E Ratio
- RQI N/A
- ANIP N/A
- Revenue Growth
- RQI N/A
- ANIP 38.68
- 52 Week Low
- RQI $9.17
- ANIP $52.50
- 52 Week High
- RQI $12.64
- ANIP $99.50
- Technical
- Relative Strength Index (RSI)
- RQI 50.69
- ANIP 66.91
- Support Level
- RQI $12.41
- ANIP $96.08
- Resistance Level
- RQI $12.67
- ANIP $99.39
- Average True Range (ATR)
- RQI 0.14
- ANIP 2.48
- MACD
- RQI -0.01
- ANIP -0.78
- Stochastic Oscillator
- RQI 40.48
- ANIP 73.14
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.